Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies

Malaria Journal

Table 1 Summary of study participant characteristics

Study name	Study design	8-AQ duration	Dose	Adult dose (mg)^a	Total adult dose (mg)	Malaria	Country	Setting	Population	Age	PQ compared to placebo in G6PD deficient people	PQ in G6PD deficient compared to G6PD replete people
Primaquine
Krudsood [24]	Randomized control trial	7 days	30 mg	30	210	Yes	Thailand	Patients	Primary care urban	16–51 years	No	Yes
Shekalaghe [22]	Randomized control trial	Once	0.75 mg/kg	45	45	Yes	Tanzania	Residents	Rural	3–15 years	Yes	Yes
Shekalaghe [23]	Randomized control trial	Once	0.75 mg/kg	45	45	No	Tanzania	Residents	Rural	1–11 years	Yes	Yes
Eziefula [27, 33]	Randomized control trial	Once	0.1, 0.4 or 0.75 mg/kg	6, 24, 45	6, 24, 45	Yes	Uganda	Residents	Unknown	1–10 years	Yes	Yes
Kheng [30]	Open parallel clinical trial	Once	0.75 mg/kg	45	45	No	Cambodia	Healthcare centres		Adults and children	No	Yes
Bancone [29]	Cohort study	Once	0.25 mg/kg	15	15	No	North-Western Myanmar–Thailand border	Residents	Rural	Adults and children	No	Yes
Ley [31]	Cohort study	Once	0.75 mg/kg	45	45	Yes	Bangladesh	Healthcare	Rural	Adults and children	No	Yes
Mwaiswelo [28]	Randomized control trial	Once	0.25 mg/kg	15	15	Yes	Tanzania	Dispensary	Town	Men and non-pregnant, non-lactating women aged ≥1 year	Yes	Yes
Tafenoquine
Rueangweerayut [32]	Cohort study	Once	100 mg (1.67 mg/kg), 200 mg (3.33 mg/kg), 300 mg (5.00 mg/kg)	100, 200, 300	100, 200, 300	No	Thailand	Laboratory	Research institute	18–45 years	No	Yes

ISSN: 1475-2875